Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
Scientific Reports|May 31, 2023
Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in JapanYuko Kanbayashi, Tadashi Shimizu, Asuka Kojima, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|February 15, 2014
DCP-LA-phosphatidylinositol and its enantiomer exhibit different bioactivitiesAyako Tsuchiya, Takeshi Kanno, Tadashi Shimizu, et al.
Anticancer Research|April 30, 2022
Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting SystemMisui Kashiwagi, Tadashi Shimizu, Rika Kawai, et al.
In Vivo (Athens, Greece)|June 27, 2025
Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting DatabaseSho Masago, Kenta Yamaoka, Mayako Uchida, et al.
The Journal of Urology|December 11, 2003
Management of renal angiomyolipomas associated with tuberous sclerosis complexToru Harabayashi, Nobuo Shinohara, Hidenori Katano, et al.
Clinical Imaging|March 9, 2005
Assessment of renal cell carcinoma after cryoablation using contrast-enhanced gray-scale ultrasound: a case seriesQiang Zhu, Tadashi Shimizu, Hideho Endo, et al.
Molecules (Basel, Switzerland)|December 24, 2014
1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol may be a promising anticancer drugTomoyuki Nishizaki, Takeshi Kanno, Ayako Tsuchiya, et al.
The Oncologist|September 23, 2025
Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse event spontaneous reporting databaseKenta Yamaoka, Sho Masago, Mayako Uchida, et al.
Oncology|June 6, 2023
Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance DatabaseKenta Yamaoka, Masaki Fujiwara, Mayako Uchida, et al.
In Vivo (Athens, Greece)|February 27, 2026
Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference GroupMasaki Fujiwara, Shuji Nagano, Yoshihiro Uesawa, et al.
Pageof 18